UK markets closed

Mainz Biomed B.V. (MYNZ)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
9.40+0.10 (+1.08%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.30
Open9.47
Bid9.40 x 1300
Ask10.00 x 1200
Day's range9.30 - 9.57
52-week range7.80 - 30.00
Volume1,867
Avg. volume28,193
Market cap131.229M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.62
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est25.00
  • Globe Newswire

    Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

    Multi-center clinical trial impacting ColoAlert’s profile for FDA submissionOn track to report results by early 2023 BERKELEY, Calif. and MAINZ, Germany, June 28, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has enrolled the first patient in ColoFuture, an international clinical study assessing the potential to integrate a portfolio of novel gen

  • Globe Newswire

    Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission

    Jane Edwards, CCRA, RAC brings over 20 years of senior experience developing optimal product and clinical trial strategies in diagnostics and medical devices Will manage the design and logistical operations of Mainz Biomed’s clinical trials in the US and Europe to support FDA submission BERKELEY, Calif. and MAINZ, Germany, June 14, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detectio

  • Globe Newswire

    Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance

    New and stringent EU regulation on in vitro diagnostic medical devices sets a higher standard of quality and safety for in vitro diagnostic (IVD) products and manufacturer processBERKELEY, Calif. and MAINZ, Germany, June 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it has successfully completed the conformity assessment of its internal pro